Glutathione S-transferase P1 (GSTP1) is markedly downregulated in prostate cancer and prostatic intraepithelial neoplasia compared to normal prostate tissue. Downregulation of GSTP1 may, therefore, be an early event in prostate carcinogenesis. An A?G polymorphism at nucleotide 313 results in an amino acid substitution (Ile105Val) in the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1. In a study of 36 prostate cancer patients, Harries et al. reported that the Ile/Ile genotype is associated with a decreased risk of prostate cancer (odds ratio 0.4 (0.17 -0.82)). We sought to confirm this finding and to examine the impact of this polymorphism together with several related polymorphisms implicated as risk factors for carcinogen-associated malignancies. One hundred and seventeen patients with prostate adenocarcinoma and 183 population-based controls were recruited to this case -control study. Genotyping of the GSTP1 (Ile105Val), GSTM1 (null), GSTT1 (null) and CYP1A1 (Ile462Val) genes was performed using polymerase chain reaction (PCR) based techniques on DNA prepared from peripheral blood. A questionnaire was used to collect demographic information from each subject. Cases were significantly older (P < 0.0001) and had significantly greater family history of prostate cancer (P < 0.0001), confirming known risk factors for this disease. By w 2 analysis, none of the genotype distributions varied among cases and controls. Using a logistic regression model to control for known risk factors we were also unable to demonstrate a significant association with prostate cancer for any of the polymorphisms tested. This population fails to identify a relationship between the above polymorphisms and prostate adenocarcinoma.
Introduction
Family history of prostate cancer is, save for age, the strongest predictor of prostate cancer risk. 1 -3 Only a fraction, approximately a fifth, of inherited prostate cancer risk can be explained by Mandelian inheritance of cancer susceptibility genes. 4 Genetic polymorphisms that alter the function or expression of genes that participate in prostate carcinogenesis may also contribute to inherited prostate cancer risk. Genes involved in hostcarcinogen interactions are the focus of this investigation.
GSTP1 4
The glutathione S-transferase P1 isoenzyme (GSTP1) is a phase II detoxification enzyme. In contrast to most cancers, 5 prostate carcinogenesis is associated with marked downregulation of GSTP1. GSTP1 is expressed predominantly in the basal layer of the normal prostate epithelium. Although normal prostate secretory cells do not routinely express GSTP1, they remain capable of expressing this enzyme and retain an unmethylated GSTP1 promoter. 6 Increased GSTP1 expression is seen in secretory cells of atrophic prostate epithelium, supporting the notion that the enzyme remains inducible in this cellular compartment. 6 GSTP1 expression is markedly diminished in an overwhelming majority of adenocarcinoma and prostatic intraepithelial neoplasia (PIN) specimens. 7 -9 In both cancer and PIN, this downregulation occurs at the transcription level and is thought to be mediated by hypermethylation of deoxycytidine residues in the CGrich promoter region located 5 0 of the transcriptional start site. 7,10 -13 Events leading up to GSTP1 inactivation during prostate carcinogenesis remain unclear. Several investigators have speculated that the early loss of GSTP1 function leads to increased vulnerability to oxidant and heterocyclic amine carcinogens, both implicated in prostate carcinogenesis. 14 -16 Nelson and colleagues demonstrated that GSTP1 overexpression confers partial resistance to the cytotoxic effects of 2-hydroxyamino-1-methyl-6-phenylimidazo [4,5-b] pyridine, the most abundant mutagenic heterocyclic amine found in cooked meats. 17 It is therefore also possible that heritable differences in GSTP1 function may also be associated with prostate cancer development.
An A?G polymorphism at nucleotide 313 results in an amino acid substitution (Ile105Val) in the substrate binding site of GSTP1. 18 The substitution of the less bulkier and more hydrophobic valine results in substrate-dependent alterations of GSTP1 catalytic activity. 18, 19 A second polymorphism, a C?T transition at nucleotide 341 results in a Ala114Val amino acid substitution. This polymorphism is linked to the Ile105Val polymorphism and does not appear to result in significant additional alteration in enzymatic function. 18 For this reason, this linked polymorphism is not examined in this study.
In a study of 36 prostate cancer patients, Harries et al. reported that the Ile/Ile genotype is associated with a decreased risk of prostate cancer (OR ¼ 0.4 (0.17 -0.82)). 20 Kote-Jarai found a trend towards a protective effect of Ile alleles. 21 In contrast to this finding, Gsur et al found that the Val/Val genotype was protective (OR ¼ 0.24 (0.09 -0.61)) in a study of 322 men with either newly diagnosed prostate cancer or benign prostatic hypertrophy. 22 Three investigators reported no effect of this polymorphism on prostate cancer risk. 23 -25 
GSTM1
The glutathione S-transferase M1 isoenzyme (GSTM1) is homozygously deleted in about one-half of the population of Europe and the United States. 26 -28 A trend towards increased risk of prostate cancer was seen in Japanese men (OR ¼ 1.3 (0.82 -2.04)) and appeared to be additive with risk associated with a CYP1A1 polymorphism. 29 No association between this polymorphism and prostate cancer risk was seen in several studies of a predominantly Caucasian population. 21 -23,25,30,31 
GSTT1
There exists a deletion polymorphism (null mutation) of GSTT1 with about 38% of the population deficient in the enzyme. 32 The available information about GSTT1 null mutations and prostate cancer risk is conflicting. Two studies of predominantly Caucasian population suggested a modestly elevated risk (OR ¼ 1.83 (1.19 -2.80)) 30 (OR ¼ 2.31 (1.17 -4.59)), 25 while three others failed to confirm these results. 21, 22, 33 No relationship between GSTT1 genotype and prostate cancer risk was found in a study of Japanese men. 34 
CYP1A1
A polymorphism exists in the CYP1A1 gene consisting of a single base change at codon 462 in exon 7 (Ile462Val) that codes for either an Ile or a Val. 35 The Val allele codes for a more inducible form of the enzyme and the Val/Val genotype is associated with an increased risk of prostate cancer (OR ¼ 2.6 (1.11 -6.25)) and the presence of a single Val allele results in a trend towards an increased risk of prostate cancer (OR ¼ 1.4 (0.86 -2.29)) in Japanese men. 29 In the study reported here, we have investigated a largely Caucasian population of cases and controls for which we have obtained information concerning other known risk factors. Our hypothesis was, that because GSTP1 is downregulated early in prostate carcinogenesis, the polymorphism, which reduces GSTP1's enzymatic activity, may be associated with increased risk of prostate cancer. In addition to GSTP1, we examined several closely related genes, known to mediate host-carcinogen interaction, because of the possibility that GSTP1 may interact with these genes during carcinogenesis.
Materials and methods

Population samples
Study subjects were recruited from the Portland, Oregon area. Individuals with adenocarcinoma of the prostate (cases) were recruited from the Urology and Medical Oncology clinic at Oregon Health Sciences University and Portland VA Medical Center. The two institutions serve a broad mix of referral, general community and indigent patients. Controls were recruited primarily by advertisement. Eligibility criteria for cases was age 18 or greater, histologically proven adenocarcinoma of the prostate and ability to give informed consent. Eligibility for controls was age 18 or greater, male gender, and lack of any malignancy (except non-melanoma skin cancer). After giving informed consent, study subjects were administered a questionnaire regarding age, race, ethnicity, and family history of cancer. This study was approved by the Institutional Review Boards of Oregon Health Sciences University and Portland VA Medical Center.
DNA preparation
DNA was isolated from peripheral blood lymphocytes using either Ficoll gradient centrifugation followed by Proteinase K digestion and phenol -chloroform extraction 36 or by use of the Puregene TM method (Gentra Systems, Minneapolis, MN, USA). DNA samples were serially numbered upon arrival in the laboratory to ensure subject confidentiality.
Polymerase chain reaction (PCR) techniques
PCR was carried out in a total volume of 50 ml, containing 0.2 -1.0 mg of genomic DNA; 400 mM each of dATP, dCTP, dGTP and dTTP; 10x PCR buffer containing 1.5 mM of MgCl 2 ; 50 mM of each primer; 1.25 units of Taq DNA polymerase (Promega) and cycled in a thermal cycler (MJ Research Inc., PTC 200). Amplification products were resolved on an agarose gel containing ethidium bromide and DNA bands were visualized by ultraviolet transillumination.
GSTP1 (Ile105Val, A313G) polymorphism GSTP1 genotyping was done following the methods of Ali-Osman and co-workers. 18 Briefly, exon 5 together with segments of surrounding introns were amplified by PCR and subsequently digested by Tail which digests the mutant but not the wild type. The primers were 5 0 -CCAGGCTGGGGCTCACAGACAGC-3 0 and 5 0 -GGTCA-GCCCAAGCCACCTGAGG-5 0 . The reactions were cycled for 94
C for 1 min, 53.5 C for 1 min and 72 C for 1 min.
GSTM1 null polymorphism
The PCR assay for deletion of GSTM1 presence or deletion was performed as described by Comstock and coworkers. 37 Co-amplification of exon 4 of the HPRT gene was used as a positive internal control. The primers were 5 0 -CTGCCCTACTTGATTGATGGG-3 0 and 5 0 CTGGATTG-TAGCAGATCATGC-3 0 . The reaction was cycled 35 times at 94 C for 20 s, 55 C for 1 min and 1 min extension at 72 C.
GSTT1 null polymorphism
The method for detecting the presence or absence of GSTT1 was modified from Pemble et al 32 
CYP1A1 (Ile462Val, A4889G) polymorphism
We developed a restriction fragment length polymorphism (RFLP) assay for the genotyping of CYP1A1 alleles. We amplified a 180 bp portion of the CYP1A1 gene using 
Statistical analysis
Different races are likely to have different genotype distributions for the polymorphisms. Since the study contained so few non-Caucasian individuals (5.1% non-white), data analysis was restricted to Caucasian subjects. Odds ratios and 95% confidence intervals were calculated by comparing genotype frequencies in the case population to the control population by standard methods. 38 The referent genotypes are shown in Table 1 .
Because cases and controls differed significantly with respect to age and family history, both known risk factors for prostate cancer, further analysis was performed to examine if imbalance in these risk factors contributed to the outcome. First the odds ratios were calculated separately for cohorts below and above the median age of the entire study population in a stratified analysis. Then multiple logistic regression was used to model the effects of known risk factors (ie age, family history), genotypes for each of the various polymorphisms, and the interactions of genotypes and known risk factors. Statistical analyses were performed using the SPSS and Stat View 5.0 statistical packages.
Results
Demographics
One hundred and seventeen individuals with prostate cancer (cases) and 183 controls were recruited. Demographic data for the two groups are illustrated in Table 2 . The case subjects were significantly older (P < 0.0001) and had a more extensive family history (P < 0.0001) than control subjects. 
Polymorphism frequencies in cases and controls
Individual genes were first analysed using w 2 analysis and these results are summarized in Table 1 . None of the polymorphism frequencies differed significantly between the cases and controls. For those polymorphisms where multiple comparisons were possible (GSTP1 and CYP1A1) all possible comparisons were examined and none yielded a significant difference between cases and controls (data not shown). The minimum odds ratios detectable with 80% power are also shown in Table 1 .
Stratified analysis and logistic regression
The control population in this study was a convenience sample and cases and controls were not balanced for other, non-genetic risk factors known to be important in prostate cancer risk. When each genotype was examined in strata below and above the median age of the entire study population (age 59), the odds ratios where consistent across strata and consistent with results for the entire study population (data not shown). To explore this issue further, we performed a logistic regression analysis of our data to control for the effect of known risk factors. In our initial analysis we examined age and family history in first degree relatives, which have been previously associated with prostate cancer. 40 As expected, age and family history were predictive of case status (Table 3 , P < 0.0001 for age and P ¼ 0.0002 for family history). The information regarding genotype for each of the polymorphisms tested was then tested to determine its effect adjusted for age. Each polymorphism was added to the analysis individually. The results of this analysis indicated no significant association of any of the tested polymorphisms in predicting case/control status (Table 3 , P > 0.1). Finally, to look for potentially important synergies between polymorphisms, each of the polymorphisms was added in combination to the analysis using both additive and multiplicative models (data not shown). Again, there were no significant associations observed between any of the combined genotypes and the risk of adenocarcinoma of the prostate.
Discussion
In this population, we examined and were unable to identify an increased risk for prostate cancer conferred by several polymorphisms that have been reported to increase the risk of other malignancies.
In the process of identifying and confirming genetic and other risk factors for prostate cancer, it is important that initial reports undergo confirmation. In follow-up studies, it is important that the data obtained include information regarding other known non-genetic risk factors for prostate cancer. In the case of prostate cancer, these risk factors include most importantly race, age and family history of prostate cancer.
The previous report that the Ile/Ile genotype of the glutathione S-transferase, GSTP1, was associated with a reduced risk of prostate cancer was based on only a small population of 36 prostate cancer patients. In the larger population of cases and controls reported here, no significant effect of GSTP1 genotype on prostate cancer risk was identified. Likewise, no effect of polymorphisms in the GSTM1, GSTT1 or CYP1A1 genes was detected. Polymorphisms in several of the human Phase II detoxification enzymes have been associated with altered risk of cancer, particularly tobacco-associated cancers such as lung and bladder. In the case of tobacco-associated cancers such effects are plausible because genetic changes in the activity of detoxification enzymes should alter cellular exposure to carcinogens. In the case of adenocarcinoma of the prostate there is no clear link between exposure to tobacco products or other carcinogens and subsequent risk of prostate cancer.
There is, however, a biological link between prostate carcinogenesis and GSTP1 expression. This link made it particularly important to attempt to confirm whether GSTP1 genotypes alter prostate cancer risk. This link provides a plausible biological mechanism by which a GSTP1 polymorphism might alter prostate carcinogenesis. During development of prostate cancer, GSTP1 expression is markedly down-regulated. The exact mechanism of this downregulation of GSTP1 expression *Estimated odds ratio from logistic coefficients. Genotype comparisons as described in Table 2 .
and the role that decreased GSTP1 expression plays in prostate cell tumorigenesis is as yet unclear. The GSTP1 protein appears to have other functions than to catalyze conjugation of nucleophiles to glutathione. Recently, Adler and co-workers have reported that GSTP1 can act to alter intracellular signaling through an interaction with Jun N-terminal kinase (JNK). 41 Decreased GSTP1 expression might therefore alter intracellular signaling and this effect would provide a plausible biochemical mechanism to explain a role in prostate carcinogenesis. The description of the effect of TER 199, a highly specific GSTP1 inhibitor, in stimulating growth of granulocytes further suggests a potentially important regulatory role for the GSTP1 protein. 42 In summary, in order to address the effect that different genotypes may have on altering the risk of developing prostate cancer, we conducted a case -control study of four genetic polymorphisms and their association with prostate cancer. We were unable to demonstrate a significant association for the development of prostate cancer in individuals bearing the Val substitutions in GSTP1, the null alleles of GSTM1 and GSTT1, or the Val encoding alleles of the CYP1A1 gene. Finally, using logistic regression analysis, we found no significant interactions between any of the polymorphisms tested.
